BL M05D1
Alternative Names: BL-M05D1Latest Information Update: 29 Aug 2025
At a glance
- Originator Sichuan Baili Pharmaceutical; SystImmune
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 Jul 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Recurrent) in USA (IV) (NCT07021066)
- 13 Jun 2025 SystImmune plans to initiate a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) (IV) (NCT07021066)
- 19 Apr 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT06349811)